Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Dahi, Parastoo B  [Clear All Filters]
Journal Article
Pennisi M, Jain T, Santomasso BD, Mead E, Wudhikarn K, Silverberg MLynne, Batlevi Y, Shouval R, Devlin SM, Batlevi C, et al. Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. Blood Adv. 2020;4(4):676-686.
Shah GL, DeWolf S, Lee YJoo, Tamari R, Dahi PB, Lavery JA, Ruiz JD, Devlin SM, Cho C, Peled JU, et al. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020.
Shah N, Dahi PB, Ponce DM, Sauter CS, Shaffer BC, Chung DJ, Politikos I, Lin RJ, Giralt SA, Papanicolaou G, et al. HEMATOPOIETIC CELL TRANSPLANTATION IS FEASIBLE IN PATIENTS WITH PRIOR COVID-19 INFECTION. Transplant Cell Ther. 2021.
Merryman RW, Redd R, Jeter E, Wong JL, McHugh K, Reynolds C, Nazzaro M, Varden A, Brown JR, Crombie JL, et al. Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with and without pembrolizumab maintenance therapy in patients with lymphoma. Transplant Cell Ther. 2021.
Brambilla CZuanelli, Lobaugh SM, Ruiz JD, Dahi PB, Goldberg AD, Young JW, Gyurkocza B, Shaffer BC, Ponce DM, Tamari R, et al. Relapse after allogeneic stem cell transplantation of acute myeloid leukemia and myelodysplastic syndrome and importance of second cellular therapy. Transplant Cell Ther. 2021.
Naik S, Riches M, Hari P, Soyoung K, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, et al. Survival Outcomes of Allogeneic Hematopoietic Cell Transplants with EBV positive or EBV negative Post Transplant Lymphoproliferative Disorder (PTLD), A CIBMTR Study. Transpl Infect Dis. 2019:e13145.